Roche and Ionis Collaborates to Develop Ionis's IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M
Shots:
- Ionis to get $75M upfront plus $684M as development- regulatory- sales milestones- license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for conducting P-II trial for IONIS-FB-LRx in patients with Geographic Atrophy (GA)
- Under the agreement- Roche has option to license IONIS-FB-LRx post trial completion and will hold global development and commercialization rights
- IONIS-FB-LRx is an antisense drug used for reduction of Factor B(FB) in patients with GA and is developed by Ionis' LIgand Conjugated Antisense (LICA) technology
Ref: Ionis Pharma | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com